Literature DB >> 9012481

Differential loss of heterozygosity in the region of the Cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas.

D J Marsh1, Z Zheng, J Zedenius, H Kremer, G W Padberg, C Larsson, M Longy, C Eng.   

Abstract

The susceptibility gene for Cowden disease (CD), an autosomal dominant inherited cancer syndrome, has recently been mapped to an approximately 6-cM interval on chromosome subband 10q22-23 between the markers D10S541 and D10S564. CD is characterized by hamartomas of many organ systems, including the thyroid, breast, skin, and gastrointestinal tract, as well as carcinoma of the thyroid and breast. Follicular thyroid adenomas and carcinomas are significant component tumors in CD; thus, we sought to examine their sporadic counterpart tumors for loss of heterozygosity (LOH) of microsatellite markers in the 20-cM region within and flanking the Cowden critical interval. In all, 38 sporadic thyroid tumors were analyzed. LOH within the CD interval was observed in 5 of 19 (26%) follicular thyroid adenomas and 1 of 9 (11%) Hürthle cell adenomas. Furthermore, of these adenomas with LOH, 3 of 4 (75%) were atypical follicular adenomas, whereas 2 of 15 (13%) were typical follicular adenomas. Surprisingly, no LOH was detected in this region in 10 follicular carcinomas. The shortest region of overlap includes the markers D10S1735 and D10S1739. If the LOH observed in these sporadic tumors is related to the CD gene, then the Cowden critical interval can be revised to lie within the interval defined by D10S579 and D10S564. LOH in this narrow interval implicates the CD gene, or another gene in that interval, in follicular thyroid tumorigenesis. However, this does not explain the lack of LOH in follicular carcinomas. Taken together, it may instead be evidence against a stepwise progression from atypical adenomas to carcinomas. Alternatively, sporadic thyroid adenoma formation may be independent of that locus, but loss of this region could prevent carcinoma formation, thus implying that the CD gene may be an oncogene or growth promoter.

Entities:  

Mesh:

Year:  1997        PMID: 9012481

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Identification of a novel PTEN mutation (L139X) in a patient with Cowden disease and Sjögren's syndrome.

Authors:  A M Raizis; M M Ferguson; B A Robinson; C H Atkinson; P M George
Journal:  Mol Pathol       Date:  1998-12

Review 2.  Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects.

Authors:  N J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

3.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

4.  Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells.

Authors:  Michele I Vitolo; Michele B Weiss; Marta Szmacinski; Khola Tahir; Todd Waldman; Ben Ho Park; Stuart S Martin; David J Weber; Kurtis E Bachman
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

5.  Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation.

Authors:  Frank Weber; Lei Shen; Koichi Fukino; Attila Patocs; George L Mutter; Trinidad Caldes; Charis Eng
Journal:  Am J Hum Genet       Date:  2006-04-12       Impact factor: 11.025

6.  Association of p53 genomic instability with the glutathione S-transferase null genotype in gastric cancer in the Portuguese population.

Authors:  A R Conde; G Martins; C Saraiva; J Rueff; C Monteiro
Journal:  Mol Pathol       Date:  1999-06

7.  Papillary carcinoma occurring within an adenomatous goiter of the thyroid gland in Cowden's disease.

Authors:  K Kameyama; H Takami; K Miyajima; T Mimura; Y Hosoda; K Ito; K Ito
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

8.  Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma.

Authors:  P Mendes-da-Silva; A Moreira; J Duro-da-Costa; D Matias; C Monteiro
Journal:  Mol Pathol       Date:  2000-08

9.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

10.  Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype.

Authors:  M Longy; V Coulon; B Duboué; A David; M Larrègue; C Eng; P Amati; J L Kraimps; A Bottani; D Lacombe; D Bonneau
Journal:  J Med Genet       Date:  1998-11       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.